利妥昔单抗联合环磷酰胺诱导缓解ANCA血管炎
本回顾性研究纳入129例新发或复发ANCA血管炎患者(BVAS-WG≥3),采用利妥昔单抗联合短程低剂量口服环磷酰胺及加速泼尼松减量方案。中位4个月达完全缓解,5个月时84%缓解;8个月中位泼尼松剂量0 mg/d,严重感染多见于血浆置换者。
要点
- 联合方案可快速减停激素,5个月84%完全缓解。
- 严重感染与血浆置换、高龄及弥漫性肺泡出血相关。
- PR3-ANCA患者RPGN时eGFR改善优于MPO-ANCA。
核心结论
- 利妥昔单抗联合短程低剂量环磷酰胺及加速泼尼松减量方案有效且耐受性良好。
研究设计与样本
- 回顾性研究,纳入129例新发或复发ANCA血管炎且BVAS-WG≥3并接受标准化诱导方案的患者。
主要发现
- 中位达完全缓解时间4个月(IQR 3.9-4.4),5个月时84%患者完全缓解。
- 8个月时中位泼尼松剂量0 mg/d(IQR 0-2.5)。
- RPGN患者中,PR3-ANCA较MPO-ANCA在6个月时eGFR提升更大(16 vs. 5.6 ml/min per 1.73m2;P=0.028)。
- 缓解后1年内122患者年仅发生1次主要复发。
- 严重感染在接收血浆置换者中更常见,并与年龄增长及弥漫性肺泡出血相关;4例死亡中3例与严重感染相关。
关键数值与推荐
- 完全缓解定义为BVAS-WG为0且泼尼松剂量≤7.5 mg/d。
临床怎么用
- 该联合方案可用于ANCA血管炎诱导缓解,实现快速减停高剂量糖皮质激素。
- 对接受血浆置换、高龄或合并弥漫性肺泡出血者需警惕严重感染。
局限性
- 回顾性研究设计可能引入选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral cyclophosphamide and an accelerated prednisone taper. METHODS: Patients were included in this retrospective study if they had newly diagnosed or relapsing ANCA vasculitis with a Birmingham Vasculitis Activity Score for Wegener Granulomatosis (BVAS-WG) ≥3 and received a standardized remission induction regimen. The primary outcome was complete remission, defined as a BVAS-WG of 0 and a prednisone dose of ≤7.5 mg/d. RESULTS: We identified 129 patients who met the inclusion criteria, 31% of whom also received plasma exchange (PLEX) for rapidly progressive glomerulonephritis (RPGN) or diffuse alveolar hemorrhage. Seventy percent of patients had myeloperoxidase (MPO)-ANCA and 9% had relapsing disease. Median time to complete remission was 4 months (interquartile range [IQR] 3.9-4.4), and by 5 months 84% of patients were in complete remission. Prednisone was tapered to discontinuation as tolerated, such that the median prednisone dose at 8 months was 0 mg/d (IQR 0-2.5). In patients with RPGN, proteinase 3-ANCA was associated with a greater increase in eGFR at 6 months compared with MPO-ANCA (16 vs. 5.6 ml/min per 1.73m2; P = 0.028). During the year following remission, 1 major relapse occurred over 122 patient-years. Serious infections occurred more frequently in patients receiving PLEX and were associated with increasing age and diffuse alveolar hemorrhage. Four deaths occurred, 3 of which were associated with serious infections. CONCLUSION: Combination therapy was efficacious, allowed for rapid tapering of high-dose glucocorticoids and was well tolerated.
引用
- Cortazar FB, Muhsin SA, Pendergraft WF, et al. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney Int Rep. 2017. PMID: 29725643. doi:10.1016/j.ekir.2017.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。